相关实验视频

Updated: Jun 21, 2025

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

通过Fyn Tyrosine Kinase抑制对Papaveroline作为阿尔茨海默病的In Silico药物候选物的计算洞察力

Shreya Satyanarayan Bhat¹, Spoorthi R Kulkarni¹, Akshay Uttarkar¹

¹Department of Biotechnology, R V College of Engineering (Affiliated to Visvesvaraya Technological University, Belagavi 590018), Bangalore, 560059, India.

Molecular biotechnology

|July 14, 2024

概括

通过抑制Fyn Tyrosine Kinase,Papaveroline显示出作为阿尔茨海默病 (AD) 治疗的潜力. 这项研究强调了它对神经退行性疾病药物发现的前景.

科学领域:

神经科学是一个神经科学.
药理学药理学是指药理学的学科.
计算化学计算化学

背景情况:

阿尔茨海默氏症 (AD) 是全球卫生面临的一个重大挑战.
氨基氨酸激酶 (Fyn Tyrosine Kinase) 参与了阿尔茨海默氏症的发病,使其成为治疗点.
对于有效的AD治疗,需要新的候选药物.

研究的目的:

为了研究Papaveroline作为一种潜在的AD药物候选药物.
为了评估Papaveroline在向Fyn Tyrosine Kinase方面的有效性.
为了探索Papaveroline与Fyn Tyrosine Kinase的结合相互作用和稳定性.

主要方法:

高通量虚拟选和定量结构-活动关系 (QSAR) 分析.
对类似药物的特性和ADMET参数的评估.
200-ns分子动力学模拟来分析结合相互作用.

主要成果:

帕帕维罗林显示出作为Fyn 铁氨酸激酶的抑制剂的潜力.
详细了解了Papaveroline-Fyn复合物的结合机制和稳定性.
与天然和参考化合物相比,Papaveroline表现出独特的特征.

结论:

帕帕维罗林是一种有前途的候选药物,用于针对AD治疗中的Fyn Tyrosine Kinase.
这些发现为神经退行性疾病的药物发现提供了新的途径.
这项研究推进了对AD病变发生过程中的分子相互作用的理解.

关键词:

在ADME研究中,研究人员研究了ADME的研究.阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.在Fyn Tyrosine 激酶中.在MMGBSA中,我们可以看到MMGBSA.超动力学是什么?超动力学是什么?分子对接是分子对接.分子动态模拟的分子动态模拟.这就是Papaveroline.

更多相关视频

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

相关概念视频

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Drugs Affecting Neurotransmitter Synthesis

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...